Indications for BIORPHEN:
Treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
Initially 40–100mcg by IV bolus, additional doses may be administered every 1–2 minutes as needed; up to max total dose of 200mcg.
Exacerbation of angina (in those with severe arteriosclerosis or history of angina). Heart failure. Pulmonary arterial hypertension. Extensive peripheral vascular disease. Monitor renal function. ESRD. Autonomic dysfunction (eg, spinal cord injury). Avoid extravasation. Elderly. Pregnancy. Nursing mothers.
Potentiated by oxytocic drugs, tricyclic antidepressants, MAOIs, angiotensin, aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot derivatives. Antagonized by alpha-adrenergic antagonists, PDE-5 inhibitors, mixed alpha- and beta-receptor antagonists, calcium channel blockers (eg, nifedipine), benzodiazepines, ACE inhibitors, reserpine, guanfacine.
Nausea, vomiting, headache; vasoconstriction, ischemia, severe bradycardia, renal toxicity.